Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. (August 2014)

• Record Type: Journal Article
• Authors: Donato, Francesca; Gay, Francesca; Bringhen, Sara; Troia, Rossella; Palumbo, Antonio
• Is Part Of: Expert opinion on biological therapy. Volume 14:Number 8(2014:Aug.)
• Page Start: 1127
• Page End: 1144
• Publication Date: 2014-08
• Subjects: antibodies -- monoclonal -- multiple myeloma; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1517/14712598.2014.908848
• Languages: English
• ISSNs: 1471-2598

Abstract

Abstract : Introduction: Despite the introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, multiple myeloma (MM) remains an incurable disease and new therapies are needed. mAbs are a new promising anticancer treatment option. Areas covered: This review will focus on mAbs that are currently under evaluation in Phase II and III clinical trials, as single agent and in combination with established treatment options. Expert opinion: mAbs are a new strategy against MM, and they have demonstrated encouraging results in preclinical models. mAbs have a relatively benign side-effect profile and work synergistically with traditional chemotherapies and with immunomodulatory drugs and proteasome inhibitors.